The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
: Did the 708 prescriptions as of February 28 equate to 708 patients, given what you said about each script usually being written for a year? Or are
any of those scripts refill? And to make sure when you say a script is written for a year, are you saying that's like a script for the first month of therapy
and has 11 refills? Or is it the single script really written for like a full year's worth of product? Then I have a follow-up.
Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
: Okay. Great. Next one is, does the CRL for Somatrogon affect your discussions with payers at all, I guess, were any of the payers waiting to see how
that FDA decision and potential contracting with that product played out prior to finalizing contracts with Ascendis?
Question: Michelle Lim Gilson - Canaccord Genuity Corp., Research Division - Analyst
: I guess to start one for Scott. You mentioned that the revenue recognition is to the specialty distributor. Can you maybe help us understand how
much is in the channel? And then one on PTH for me too, can you remind us what kind of regulatory discussions you've had around PTH? And to
what extent the FDA had some input in the Phase III trial design and the primary endpoint. And then what really needs to be shown within the
Phase III data set to get a label as a PTH replacement therapy versus an adjunctive therapy in that differentiation from NATPARA in the labeling in
terms of what regulators want to see to differentiate, I guess, the 2 programs?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MARCH 02, 2022 / 9:30PM, ASND.OQ - Q4 2021 Ascendis Pharma A/S Earnings Call
Question: Anita Dushyanth - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst
: Just regarding the number of prescribers for SKYTROFA. I think in the commentary, you mentioned 263. Could you talk about maybe when internally,
the team -- the sales team to be able to cover the 1,400 prescribers?
|
